Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously documented CHC genotype 1 infection. Other or mixed genotypes are not eligible.~* Liver biopsy with histology consistent with CHC and no other etiology.~* Participants with cirrhosis must have an ultrasound/imaging study within 6 months of screening (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma~* Failed previous treatment (of at least 12 weeks) with pegylated interferon (alfa-2a or alfa-2b) plus RBV~* Weight between 40 kg and 125 kg, inclusive~* Of 'local' ancestral descent~* Sexually active males and females of child-bearing potential must agree to use a medically accepted method of contraception~Exclusion Criteria:~* Co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus.~* Required discontinuation of previous interferon or RBV regimen for an adverse event considered to be possibly or probably related to RBV and/or interferon.~* Treatment with RBV within 90 days and any interferon-alpha within 1 month prior to screening.~* Treatment for hepatitis C with any investigational medication or prior treatment with herbal remedies with known hepatotoxicity.~* Treatment with any investigational drug or participation in any interventional clinical trial within 30 days of the screening visit.~* Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.~* Diabetes and/or hypertension with clinically significant ocular examination findings.~* Any condition the could interfere with participation in and completion of the trial.~* Evidence of active or suspected malignancy, or history of malignancy within the last 5 years (except adequately treatment carcinoma in situ and basal cell carcinoma of the skin).~* Pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Boceprevir (Type: EXPERIMENTAL): PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
- Control (Type: ACTIVE_COMPARATOR): PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).